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Abstract
Background: This study explored Bacopa monnieri, a medicinal Ayurvedic herb, as a cardioprotectant against
ischemia/reperfusion injury using cardiac function and coronary flow as end-points.
Methods: In normal isolated rat hearts, coronary flow, left ventricular developed pressure, heart rate, and functional
recovery were measured using the Langendorff preparation. Hearts were perfused with either (i) Krebs-Henseleit
(normal) solution, (control), or with 30, 100 μg/ml B. monnieri ethanolic extract (30 min), or (ii) with normal solution
or extract for 10 min preceding no-perfusion ischemia (30 min) followed by reperfusion (30 min) with
normal solution. Infarct volumes were measured by triphenyltetrazolium staining. L-type Ca2+-currents (ICa, L)
were measured by whole-cell patching in HL-1 cells, a mouse atrial cardiomyocyte cell line. Cytotoxicity of
B. monnieri was assessed in rat isolated ventricular myocytes by trypan blue exclusion.
Results: In normally perfused hearts, B. monnieri increased coronary flow by 63 ± 13% (30 μg/ml) and 216 ± 21%
(100 μg/ml), compared to control (5 ± 3%) (n = 8–10, p < 0.001). B. monnieri treatment preceding ischemia/reperfusion
improved left ventricular developed pressure by 84 ± 10% (30 μg/ml), 82 ± 10% (100 μg/ml) and 52 ± 6% (control)
compared to pre- ischemia/reperfusion. Similarly, functional recovery showed a sustained increase. Moreover, B.
monnieri (100 μg/ml) reduced the percentage of infarct size from 51 ± 2% (control) to 25 ± 2% (n = 6-8, p < 0.0001).
B. monnieri (100 μg/ml) reduced ICa, L by 63 ± 4% in HL-1 cells. Ventricular myocyte survival decreased at higher
concentrations (50–1000 μg/ml) B. monnieri.
Conclusions: B. monnieri improves myocardial function following ischemia/reperfusion injury through recovery of
coronary blood flow, contractile force and decrease in infarct size. Thus this may lead to a novel cardioprotectant
strategy.
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Background
Disease of the myocardial vasculature including the
coronary artery is a major cause of disability and death
in spite of widespread application of highly efficacious
cardiovascular drugs. Myocardial infarction (MI) most
commonly arises from an unstable atheroma forming
fragments and clots that occlude downstream vessels
culminating in regional myocardial ischemia [1]. The
resultant energy failure has numerous cytopathological
consequences, including changes of pH and Na+ levels,
subsequently leading to reversal of Na+/Ca2+ exchange,
which in turn results in cytosolic Ca2+ loading and acti-
vation of proteolytic enzymes mediating necrosis [2].
Mitochondrial Ca2+ homeostasis also fails, leading to
disruption of the electron transport chain, cytochrome C
release and initiation of apoptosis. However, these
changes are slow during sustained occlusion [2] but
most damage begins on reperfusion. Glucose is shunted
into glycolysis producing lactic acid and mitochondrial
beta-fatty acid oxidation [2]. Early reperfusion is accom-
panied by excessive superoxide production [3] and con-
sequently leads to other reactive species which increase
cell damage and to further cytosolic Ca2+ loading [4].
Fragments of damaged cells then activate resident im-
mune cells and immune receptors on endothelial cells,
which in turn secrete inflammatory cytokines and adhe-
sion proteins, respectively. Endothelial cells generate
further superoxide via adherent xanthine oxidase, cyto-
kine activation of nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase, and oxidised nitric oxide
(NO) synthase [5]. Endothelial cells not only lose their
vasorelaxant influence over vascular smooth muscle, but
they release vasoconstrictors, especially endothelin-1 [6],
which further exacerbates the conditions causing MI.
Endothelial injury manifests as cell blebbing, swelling
and plugging culminates in “no-reflow” [7]. Thus we
have a potent cytotoxic combination of Ca2+, superoxide,
inflammation and vasoconstriction, all of which conspire
over the ensuing minutes-hours in myocardial cell
death.
Targeting these pathologies individually produces
improved recoveries in experimental animals provided
the protectant is present before ischemia begins, but
they have failed in translation. Thus at present, the
standard treatments focus on atherosclerosis by using
thrombolytics, anticoagulants or angioplasty. Clinical
applications targeting mitochondria have met with
some limited positive outcomes [2, 8]. Nevertheless, it
is clear that for any protectant to be useful, it would
have to be administered prophylactically to high risk
patients, act against the major reperfusion patholo-
gies, be cheap and have low toxicity and ideally, help
to reduce the initial risk of MI. It is unlikely that any
classical single substance or drug could perform in
this manner, but several multifunctional herbals have
the potential to fulfill such a role.
They include, a medicinal Ayurvedic herb, which is
thought to improve cardiovascular function. Thus, oral
B. monnieri given to rats for three weeks reduced bio-
chemical and histopathological perturbations caused by
ischemia/reperfusion (I/R), while increasing myocardial
antioxidant enzymes and reducing myocardial apoptotic
signaling proteins [9]. Over-dosing rats with iso-
proterenol reduced endogenous antioxidant enzymes
and increased lipid peroxidation, but less so in those ani-
mals which had been chronically treated with B. mon-
nieri [10]. Necrosis and markers of myocardial injury
were also reduced.
There is also some evidence that B. monnieri improves
systemic vascular function. It relaxes a wide range of
arteries [11], partly through endothelial NO release and
in vascular smooth muscle by inhibiting Ca2+ influx and
Ca2+ release from the sarcoplasmic reticulum [11].
Nevertheless, chronic oral administration of B. monnieri
to rats for 12 weeks increased cerebral blood flow with-
out changing blood pressure [12]. This is particularly
important because B. monnieri has been traditionally
used to enhance memory and several clinical trials sug-
gest that it does have nootropic actions [13, 14]. Further-
more, it is neuroprotective [15, 16] and the mechanism
of action is mainly related to its antioxidant and anti-
inflammatory properties [16–18]. Recently, we have
shown that B. monnieri had no signs of toxicity in either
acute or chronic oral toxicity tests of both male and
female rats, indicating that it is relatively safe [19].
Clearly, several lines of evidence point to B. monnieri
having potentially favorable cardiovascular actions
arising from the hemodynamic changes and protective
effects in vulnerable tissues as well as reducing some of
the pathological changes contributing to I/R injury.
Nevertheless, it is unclear whether these effects of B.
monnieri translate directly to improving the function of
the myocardium or whether they could ameliorate the
damage following cessation and restoration of blood
flow, i.e., I/R injury. To answer this, we aimed to show
that an extract of B. monnieri could improve myocardial
perfusion in normally beating isolated rat hearts and to
show that it produces an independent acute recovery in
cardiac function after I/R while at the same time not
creating cellular toxicity in isolated ventricular myocytes.
Methods
Preparation of B. monnieri extract
The aerial part of B. monnieri was collected from
Phetchaburi province, Thailand, and identified by
Associate Professor Wongsatit Chuakul, Faculty of
Pharmacy, Mahidol University, Thailand. The voucher
specimen (Phrompittayarat 001) was kept at the
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Pharmaceutical Botany Mahidol Herbarium, Mahidol
University, Thailand. B. monnieri was extracted using 95%
ethanol and its total saponin content, 4.19% (w/w) com-
prising bacoside A3 (0.74%), bacopaside I (0.93%), bacopa-
side II (0.98%) bacopaside X (0.53%), and bacopasaponin
C (1.00%), was determined by high pressure liquid chro-
matography as previously reported [20, 21]. The extract
was dried and stored at 4 °C until use. Its yield was 10%
(w/w of the dried plant). The B. monnieri extract was dis-
solved in Krebs-Henseleit buffer (KHB) (mM): NaCl, 118;
NaHCO3, 25; KH2PO4, 1.2; KCl, 4.5; CaCl2, 1.36; MgSO4,
1.2 and glucose 11 adjusted to pH 7.4. It was stirred for
30 min and sonicated in an ultrasonic tank at 37 °C for
another 30 min. Prior to use, the KHB and the solutions
of B. monnieri extract were filtered through a 0.8 μm
Millipore filter to remove insoluble particles.
Animals
Adult male Wistar rats (200–250 g, 7–8 weeks old) were
obtained from the National Laboratory Animal Centre,
Mahidol University, Salaya, Nakhorn Pathom, Thailand
or Charles River, L’Arbresle, France. All experimental
protocols were approved by the Animal Ethics Commit-
tee (No. NU-AE530613 and NU-AE590203), Naresuan
University, Phitsanulok, Thailand and by the local com-
mittee for ethics in animal experimentation (No. 2012-
012-CD, date 05/09/2012), Faculty of Medicine and
Pharmacy, Université de Franche Comte, Besançon,
France, and complied with the US National Institutes of
Health (NIH publication No. 85–2, revised 1996). Rats
were kept in polysulfone shoe box cage (3–4 rats/cage)
bedded with autoclaved corn cob, in temperature-
controlled rooms (22 ± 2 °C), at 50-60% humidity, with a
reversed 12:12 h diurnal cycle and standard diet and RO
water provided ad libitum. Animals were randomly
allocated for ex vivo treatment. The sample size was
calculated using R program (α = 5%, mean difference =
15, SD = 10, power = 80%).
Preparation of Langendorff heart perfusion and protocols
Effect of B. monnieri on normal and I/R hearts
Rats were anesthetized with sodium pentobarbital
(50 mg/kg, intraperitoneally) followed by heparin (250
UI/kg, intravenously). The level of anesthesia was
assessed by toe pinch and corneal reflex before the sur-
gery. The hearts were then rapidly removed and
immersed in ice-cold KHB to stop contractions, and the
myocardium was perfused retrogradely with KHB using
the Langendorff method at a constant perfusion pressure
of 80 cm of water (7.8 kPa). The perfusate was bubbled
with 95% oxygen and 5% carbon dioxide and maintained
at 37 °C. To measure left ventricular end diastolic pres-
sure (LVEDP), a water-filled latex balloon (4x8 mm,
EMKA Technologies, Paris, France) was inserted into
the left ventricle and connected to a pressure transducer
(682002, Becton Dickinson, Sandy, Utah, USA) and a
Gould TA240 Physiograph (Gould Instrument Systems,
Courtaboeuf, France). The pressure within the balloon
was adjusted to 2–8 mmHg, i.e., equivalent to the
normal LVEDP [22].
The intraventricular pressure and heart rate (HR) were
continuously recorded. The left ventricular developed
pressure (LVDP) calculated as left ventricular systolic
pressure minus LVEDP, was used as an indicator of left
ventricular systolic function. Total coronary flow was
measured by collecting aliquots of coronary venous
effluent. All hemodynamic parameters were measured at
2 min intervals. The hearts were stabilized for 10–
20 min and then the following two experimental proto-
cols (Table 1) were carried out (54 rats, n = 8-10/group).
The concentrations of B. monnieri extract were based
on earlier in vitro studies where the IC50 was around
100 μg/ml for inducing vasorelaxation in small resist-
ance arteries [11].
Effect of B. monnieri on myocardial infarct size
Rat hearts were isolated and perfused using the Langen-
dorff method as described above. The hearts were pre-
perfused with KHB (control) or KHB supplemented with
100 μg/ml B. monnieri for 30 min prior to 30 min global
ischemia followed by 2 h reperfusion, sufficient to allow
histological changes to develop [23] (14 rats, n = 8 for
control, n = 6 for treatment). After 2 h of reperfusion,
hearts were perfused for 5 min with 10 ml of 1% (w/v)
triphenyltetrazolium chloride (TTC) (Sigma, St. Louis,
MO, USA), then removed and placed in 1% TTC solu-
tion at 37 °C for 10 min [23]. The hearts were incubated
in 2.5% glutaraldehyde for 1 min, and set in 5% agarose
before sectioning in 750 μm thick slices. All slices were
incubated in 10% (v/v) formaldehyde overnight at room
temperature before re-hydration overnight with
Table 1 Experimental design of B. monnieri effect on normal
and I/R hearts
Group Treatment & Protocol
Normal hearts 1) KHB (control, n = 9)
2) 30 μg/ml B. monnieri extract (n = 10)
3) 100 μg/ml B. monnieri extract (n = 8)
Protocol: Isolated hearts were perfused with KHB alone
or KHB containing B. monnieri extract for 30 min (Fig. 1).
I/R hearts 1) KHB (control, n = 9)
2) 30 μg/ml B. monnieri extract (n = 9)
3) 100 μg/ml B. monnieri extract (n = 9)
Protocol: Isolated hearts were perfused with KHB alone
or KHB containing B. monnieri extract for 10 min and
then perfusion stopped for 30 min to emulate global
myocardial ischemia, after which 30 min perfusion was
resumed with normal oxygenated KHB (Fig. 2).
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phosphate buffer saline (PBS) at 4 °C. The heart sections
were scanned and planimetry was carried out and
surface area of the whole, and TTC-negative, myocar-
dium was transformed to volume [23]. The TTC-
negative infarction volume was expressed as a percent-
age of heart volume. All analyses of infarct size were
done by an investigator, who was blinded with regard to
the group assignments.
Electrophysiological measurements of the L-type Ca2+
current
Effect of B. monnieri (100 μg/ml) on L-type Ca2+
current (ICa, L) was studied in HL-1 cells (kind gift
from Prof. Dr. William C. Claycomb, Louisiana State
University Medical Center, LA, USA). This cell line,
derived from an atrial tumor lineage of the AT-1
mouse, spontaneously contracts and retains the
phenotypic characteristics of cardiomyocytes [24],
including the expression of L-type Ca2+ channels.
Inhibition of ICa, L by nifedipine was previously dem-
onstrated in HL-1 cells as shown in Additional file 1:
Figure S1. The whole-cell patch clamp technique was
used for recording of ICa, L. The experimental proto-
col was adopted from a previous study [25]. The
composition of the bath solution (i.e., normal Tyr-
ode’s solution) was (mM): NaCl, 140; KCl, 5.4; MgCl2,
1.1; CaCl2, 2; HEPES, 5; glucose, 10 and adjusted pH
to 7.4, osmolality, 310 mOsm. Patch pipettes were
fabricated from capillary glass tubing (Borosilicate-
standard wall with filament, 1.50 mm OD). Internal
solution was composed of (mM): NaCl, 8; MgCl2, 5.9;
HEPES, 20; Cs aspartate, 120; TEA-Cl, 20; K2-ATP, 5
(pH 7.2, osmolality, 290 mOsm). The pipette resist-
ance was 3–5 MΩ in the bath solution. Cells were
locally perfused with Tyrode’s solution plus CsCl2
(5 mM) to block K+ channels. ICa, L was recorded
using following protocols [25]: holding membrane
potential was kept at −80 mV. A pre-step to −40 mV
for 1500 ms inactivated Na+ and T-type Ca2+ channels,
then a test-step to +10 mV for 400 ms was applied to
measure L-type Ca2+ currents. Control ICa, L was re-
corded 3 times to obtain consistency of the current
of the cell chosen. Then, each cell was locally per-
fused with 100 μg/ml B. monnieri extract dissolved in
Tyrode’s solution containing CsCl2 for 1 min. Subse-
quently, currents were recorded in the presence of
the extract. Current signals were recorded with an
Axopatch 200B patch-clamp amplifier (Axon Instru-
ments, Foster City, CA) connected to a 50/60 Hz
Noise Eliminator (Hum Bug, Quest Scientific,
Canada). Data were collected using a custom-written
program (Myoclamp V2.4.1 software) for Windows.
Currents were analyzed by using IGOR Pro6 software
(Wave-Metrics). The average effect of the extract on
ICa, L was expressed as percentage change of control
ICa, L from the same cell.
Cytotoxicity of B. monnieri
Isolation of rat ventricular myocytes and culture
Ventricular myocytes were isolated from rat hearts
using collagenase as previously described [23, 26].
Hearts were excised and initially perfused in the
Langendorff apparatus for 5 min with Tyrode’s solu-
tion containing (mM): NaCl, 130; KCl, 4.5; MgCl2 1.4;
NaH2PO4, 0.4; CaCl2, 0.75; [N-(2-hydroxyethyl) pi-
perazine N′-(2-ethanesulfonic acid)] HEPES 4.2,
taurine 20, creatine 10, glucose 10, pH 7.3 and gassed
with 100% O2 at 37 °C and then perfused with Ca
2+
free Tyrode’s solution containing 100 μM EGTA for
another 4 min. This was followed by Tyrode’s solu-
tion containing 100 μM CaCl2 and 1 mg/ml
Worthington type II collagenase for 8 min. The ven-
tricles were then cut into approximately 1 mm3 pieces
and incubated in 10 ml of this collagenase solution
for 7 min with regular triturating using a Pasteur pip-
ette until cells were released. Isolated myocytes were
separated from undigested ventricular tissue by filter-
ing through cell strainer. Isolated myocytes were
allowed to settle into a loose pellet and the super-
natant was removed and replaced with Tyrode’s solu-
tion containing 1% fetal bovine serum albumin and
500 μM CaCl2. In the next step, the supernatant was
removed and replaced with Tyrode’s solution contain-
ing 1 mM CaCl2. The cell pellet was washed at room
temperature with M199 culture medium containing
100 IU/ml penicillin/streptomycin. The myocytes were
resuspended in modified M199 (containing 2 mM
creatine, 2 mM carnitine, and 5 mM taurine).
Determination of cell viability
Cell viability was assessed by trypan blue exclusion
assay [26]. After cell plating, the isolated cardiac
myocytes were replenished with modified M199 cul-
ture medium (control) or medium containing B. mon-
nieri extract (10–1000 μg/ml) for 1 h. Then the
supernatants were removed, the cells were resus-
pended in 50 μl 0.4% trypan blue solution and incu-
bated for 5 min. After that, supernatants were
removed and replaced with PBS solution. One hun-
dred cells in each well (n = 3) were randomly counted
under a light microscope. The cell viability was calcu-
lated as number of unstained cells divided by total
number of cells and expressed as a percentage.
Drugs and solution
All chemicals were purchased from Sigma (St. Louis,
MO, USA or Saint Quentin Fallavier, France). M199
medium and fetal bovine serum were from Gibco BRL,
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Life Technologies, Inc. (New York, USA). Type II
collagenase was obtained from Worthington (Lakewood,
NJ, USA).
Statistical and data analysis
All data are presented as mean ± standard error of mean
(SEM) of n animals or cells. Comparisons were assessed
using analysis of variance (two-way ANOVA) followed
by Tukey’s test or Student t-test as appropriate. Statis-
tical significance was considered at p values <0.05. To
compare the effects of B. monnieri with controls, all
hemodynamic parameters were normalized to the data
value obtained after the 10 min stabilization period, and
were expressed as %coronary flow, %LVDP, %HR, and
%functional recovery, a global index of cardiac contract-
ile function, calculated as [(HR TRx × LVDP TRx × 100)
/ HR TP10 × LVDP TP10] where TRx represents the
time of reperfusion at x min and TP10 relates to the
value at 10 min of the perfusion during stabilization
period.
Results
B. monnieri increased coronary flow in normal hearts
In normally perfused isolated rat hearts, during
stabilization, all hemodynamic parameters including cor-
onary flow (Fig. 1a), LVDP and HR remained constant
and similar in all treatment groups. Application of 30 or
100 μg/ml B. monnieri for 30 min produced a
concentration-dependent increase in coronary flow
(Fig. 1b) and LVDP (Fig. 1c). The coronary flow was 1.6-
fold increased in the presence of B. monnieri at 30 μg/
ml (mean = 168 ± 13%, n = 10), and 3.1-fold at 100 μg/ml
(mean = 321 ± 21%, n = 8) compared to control (mean =
105 ± 3%, n = 9) (Fig. 1e). There were also small in-
creases in LVDP (Fig. 1c, e), but no change in HR
(Fig. 1d, e) in response to both concentrations of B.
monnieri.
Fig. 1 B. monnieri improved hemodynamics in isolated rat hearts. a coronary flow (ml/min) using normal perfusate (control) and perfusate
containing 30 or 100 μg/ml B. monnieri extract for 30 min, b coronary flow, %, c LVDP, %, d HR, %: b-d expressed as percentage of mean data
from the same heart compared to the 10 min stabilization using normal perfusate and e mean expressed as the average of each
parameter after application of normal perfusate or perfusate containing B. monnieri extract for 15 min onward. Data are expressed as
mean ± SEM (n = 8-10 hearts) and *p < 0.05, **p < 0.001 for 30, 100 μg/ml B. monnieri compared to control, ##p < 0.001 for 30 μg/ml
compared to 100 μg/ml B. monnieri
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B. monnieri improved recovery after I/R
B. monnieri extract was added to the perfusate for
10 min whereupon coronary flow increased as above.
The perfusion was then stopped for 30 min to emulate
global ischemia after which perfusion was restored for a
further 30 min (Fig. 2a). In the control group (n = 9), all
the hemodynamic parameters were substantially reduced
compared to before ischemia (Fig. 2b-e). However, pre-
treatment with 30 or 100 μg/ml B. monnieri improved
cardiac function in I/R heart. Coronary flow was imme-
diately restored to 90 ± 10% (n = 9), and 111 ± 7% (n = 9)
with pre-exposure to 30 and 100 μg/ml B. monnieri, re-
spectively (Fig. 2b). Although coronary flow declined,
this was always higher in the B. monnieri pre-treated
groups at every time point compared to those without B.
monnieri (p < 0.001). LVDP as a measure of myocardial
contractile force, gradually increased in B. monnieri-
treated groups and maintained after reperfusion for
20 min onwards (52 ± 6%, 84 ± 10%, 82 ± 10%, for con-
trol, 30 μg/ml and 100 μg/ml B. monnieri, respectively,
p < 0.001 for B. monnieri compared to control) (Fig. 2c).
Likewise, functional recovery showed a sustained in-
crease (Fig. 2e). HR was depressed on initial reperfusion,
but there was no clear change during the recovery
period (Fig. 2d).
Pretreatment of B. monnieri reduced myocardial infarction
An ex vivo global ischemia for 30 min followed by 2 h
reperfusion resulted in the myocardial infarction up to
51 ± 2% of ventricular volume (n = 8) (Fig. 3, control).
Pretreatment with 100 μg/ml B. monnieri substantially
Fig. 2 Pretreatment with B. monnieri and recovery after myocardial ischemia in isolated rat hearts. a coronary flow (ml/min) using normal
perfusate (control) or perfusate containing 30 or 100 μg/ml B. monnieri (10 min), followed by cessation of perfusion (30 min, ischemia) and then
restoration of normal perfusate (30 min, reperfusion). b-e truncated time courses showing the post-ischemia recovery period where the values
are expressed as percentage of the mean data from the same heart compared to the 10 min stabilization using normal perfusate for b coronary
flow, %, c LVDP, %, d HR, % and e functional recovery, %, a global index of cardiac contractile function, calculated as [(HR TRx × LVDP TRx × 100) /
HR TP10 × LVDP TP10] where TRx represents the time of reperfusion at x min and TP10 relates to the value at 10 min of the perfusion during
stabilization period. Data are expressed as mean ± SEM (n = 9 hearts) and **p < 0.001 for 30 or 100 μg/ml B. monnieri compared to control
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reduced infarct size to 25 ± 2%, n = 6 (Fig. 3, p < 0.0001
vs control).
B. monnieri reduced ICa, L in HL-1 cardiac cells
Ca2+ is an important mediator of ischemic cell damage
and in cardiac muscle, an important Ca2+ influx pathway
is through L-type Ca2+ channels and blockade of these
channels can offer some protection [27, 28].
Whole-cell voltage clamping of HL-1 cardiac cells
showed transient inward currents of −71.4 ± 19.6 pA pre-
viously identified as ICa, L [25] (‘control’ in Fig. 4a). The
extract decreased the peak current amplitude of ICa, L to
about one third i.e., to 37.1 ± 4.1% compared to control (p
< 0.001, n = 4, Fig. 4b).
Cytotoxicity of B. monnieri extract
Direct effect of B. monnieri on cell viability of freshly
isolated rat ventricular myocytes was determined using
the trypan blue exclusion assay. After 1 h incubation of
ventricular myocytes with various concentrations of B.
monnieri extract (10–1000 μg/ml), cell survival was
decreased in those cells exposed to concentrations of
50 μg/ml and above (Fig. 5). High concentrations of
the extract (≥500 μg/ml) produced more than 50%
cell death (Fig. 5).
Fig. 3 The sensitivity to myocardial infarction in rat hearts subjected
to global ischemia/reperfusion, in the presence or absence of
100 μg/ml B. monnieri. The data shown is the normalised infarction
volume of isolated rat hearts in the presence of 100 μg/ml B.
monnieri extract for 30 min before the onset of 30-min global
ischemia followed by 2 h of reperfusion. The bar graphs represent
means ± SEMs (n = 8 for control and n = 6 for B. monnieri extract,
**p < 0.0001 vs control)
Fig. 4 For whole cell currents in voltage clamped HL-1 cardiac cells,
K+-currents were blocked by intracellular and extracellular Cs2+, and
Na+- and T-currents inactivated by a -40 mV holding potential, then
ICa, L activated by stepping to +10 mV (voltage profile: see inset).
a Typical trace showing inhibition of ICa, L by 100 μg/ml B. monnieri
in the same cell. b Inhibition by 100 μg/ml B. monnier of ICa, L
expressed as percentage of mean compared to average of
control ICa, L from the same cell. Data are means ± SEM (n = 4
cells from 3 cultures) and *** p < 0.001 comparing B. monnieri
vs control, paired t-test
Fig. 5 Toxicity testing of B. monnieri extract (10–1000 μg/ml) for 1 h
on rat freshly isolated ventricular myocyte viability quantified by
the trypan blue exclusion assay. Data are expressed as mean ± SEM
(n = 3) and *p < 0.05, **p < 0.01 ***p < 0.001 for B. monnieri compared
to control
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Discussion
The key findings of the present study were that B.
monnieri extract induced a concentration-dependent
improvement in coronary flow, promoted cardiac func-
tion, and reduced infarct area resulting from ischemia
and reperfusion in isolated perfused hearts. Previously,
B. monnieri was shown to dilate various isolated rat
arteries by (i) stimulating endothelial NO release, and
(ii) acting directly on vascular smooth muscle cells by
inhibiting extracellular Ca2+ influx and Ca2+ release from
sarcoplasmic reticulum [11]. Also, B. monnieri inhibits
Ca2+ influx in various tissues including several types of
isolated rat arteries [11, 29], guinea pig ileum and tra-
chea [29, 30] and rat trachea [31]. Similar mechanisms
may well operate in the coronary vasculature. Likewise,
chronic oral administration of B. monnieri increased
cerebral blood flow in normal rats [12].
Coronary blood flow is normally mediated by demands
of myocardial contraction [32]. However, in the presence
of B. monnieri coronary flow was substantially greater
than the increased LVDP, which suggests that the vascu-
lature dilated independently of myocardial needs. Never-
theless, there was a slightly increased myocardial
contractility with B. monnieri, which might be facilitated
by the augmented blood flow as seen in the canine and
rat hearts [33, 34]. Moreover, the positive ionotropic
effect of B. monnieri suggests the extract had no adverse
action on the intact myocardium.
However, there was a clear disconnect between blood
flow and contractility during post-ischemic reperfusion:
restoration of blood flow was immediate and slowly de-
clined thereafter while LVDP developed over 15 min
(Fig. 2). This implies that contractility was not solely a
direct consequence of better blood flow. One explan-
ation for this disconnect could involve Ca2+ influx,
which we show was inhibited in isolated myocytes.
On the one hand, inhibition of vascular smooth
muscle L-type Ca2+ maximises the vasodilatation
through the lingering action of B. monnieri, thus pro-
viding metabolic resources to re-establish the extra-
and intracellular milieu. At the same time, this same
action on cardiac myocytes inhibits their contraction
until the accumulated Ca2+ is cleared after which they
can re-establish sinus rhythm. This Ca2+ overloading
of cardiac myocytes has been emphasised in many
studies and various drugs targeting this overload
including Ca2+-channel blockers improve post-IR
recovery [27, 28].
Our present protocol was short-term but B. monnieri
may well have more lasting beneficial effects in vivo [9, 10].
For example, in coronary I/R, there is inflammation begin-
ning with endothelial cell blebbing and swelling followed
by platelet and leucocyte adhesion leading to microvascular
block and a “no flow” condition lasting many hours [7].
With B. monnieri, the initial flow was good but gradually
decreased with continued reperfusion for all three treat-
ment groups although the pretreated ones maintained
superior flow rates (Fig. 2). The prolonged effects of in-
flammation do not apply to the present protocol, but our
data suggest that the coronary vasculature enters this crit-
ical period with a distinct functional advantage. These anti-
inflammatory effects of B. monnieri may be mediated
through one of its constituents, betulinic acid [35, 36] by
potently blocking the inflammatory transcription factor
NF-kB or p38/ERK MAPK pathways [35] thereby prevent-
ing the augmented cytokine production [36].
Antioxidant actions are universally claimed to be an
action of most herbals including B. monnieri [9, 17]. Yet,
whatever of this antioxidant remained in the tissue on
reperfusion without extract would have little real impact
on the superoxide onslaught. Nevertheless, polyphenols
and other plant biologicals stereospecifically cause Nrf-2
nuclear translocation thereby increasing expression of
some anti-oxidant enzymes [37–40] and their activation
can provide protection against I/R [41].
Our B. monnieri extract appeared to be cytotoxic at a
threshold concentration of ~50 μg/ml but, nevertheless,
it increased LVDP suggesting that toxicity was absent in
the intact myocardium. The explanation for this discrep-
ancy may be a combination of: (i) toxicity was studied in
culture where myocytes are directly exposed to the ex-
tract, while in the perfused heart the concentration of
the extract within the extracellular space is likely to be
lower, (ii) the incubation time of cultured myocytes in
the extract was longer (1 h) than the 10 min perfusion.
Importantly, the intriguing notion is that if those com-
ponents of B. monnieri having beneficial and having
cytotoxic actions are different, the cardioprotective com-
ponents could display a greater efficacy for post-
ischemic recovery.
This study has revealed an improved coronary flow,
increased myocardial function and contracted infarct
area. The additional anti-inflammatory, antioxidant de-
fenses and reduced Ca2+-overload demonstrated in other
systems, suggest that B. monnieri might provide a multi-
pronged defense against ischemic cell death. Neverthe-
less, the model used here, and most of the animal
models for I/R poorly replicate the human condition
where the underlying vascular pathology develops over a
generation and is influenced by ‘conditioning’. Thus,
major impacts in the treatment of I/R will only become
translatable when accurate animal models for the human
condition emerge.
Conclusion
B. monnieri protected against I/R injury in rat heart as
judged by its ability to recover coronary flow, contractile
force and function, and reduced infarct volume. As such,
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it could form the basis of a promising cardioprotectant
(and cerebroprotectant) for patients at risk from infarcts.
In pursuing this, the protectant and cytotoxic compo-
nents need to be identified and plant strains or extrac-
tion protocols showing more efficacious chemical
profiles selected.
Additional file
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